Curis Says CUDC - 907 Trial Records Complete Resonse In Large B-cell Lymphoma

(RTTNews) - Curis, Inc. (CRIS) Monday announced the publication of results from the dose escalation part of the Phase 1 clinical trial of CUDC-907 in the journal Lancet Oncology. According to the company CUDC-907 demonstrated objective responses, including complete responses, in patients with relapsed/refractory diffuse large B-cell lymphoma.

The publication is also accompanied by an independent commentary in the journal titled "Dual inhibition of oncogenic targets for B-cell malignancies."

Anas Younes, chief of the Lymphoma Service of the Memorial Sloan Kettering Cancer Center in New York City and the Principal Investigator of the Phase 1 trial said, "The data from the Phase 1 monotherapy trial for CUDC-907, especially in heavily pretreated patients with relapsed/ refractory DLBCL are very encouraging and we look forward to data emerging from the current Phase 2 trial in patients with MYC-altered DLBCL."

Curis has started Phase 2 trial to evaluate CUDC-907 in patients with MYC-altered RR-DLBCL.